Literature DB >> 21764451

The effects of iridium on the renal function of female Wistar rats.

Ivo Iavicoli1, Luca Fontana, Alessandro Marinaccio, Alessandro Alimonti, Anna Pino, Antonio Bergamaschi, Edward J Calabrese.   

Abstract

Despite the widespread use of iridium (Ir) in catalytic converters for improved capacity for reducing carbon monoxide (CO), hydrocarbon (HC) and nitrogen oxide (NO(x)) emissions, there is a lack of studies that have assessed possible toxicological hazards of exposure to Ir. The present investigation indicates that female Wistar rats exposed to Ir in the drinking water for 90 days displayed renal toxicity based on the elevated urinary retinol binding protein (RBP) and albumin. The RBP was more sensitive to albumin, showing significant increases at 0.01 mg/L.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21764451     DOI: 10.1016/j.ecoenv.2011.06.014

Source DB:  PubMed          Journal:  Ecotoxicol Environ Saf        ISSN: 0147-6513            Impact factor:   6.291


  3 in total

1.  Sub-Chronic Oral Exposure to Iridium (III) Chloride Hydrate in Female Wistar Rats: Distribution and Excretion of the Metal.

Authors:  Ivo Iavicoli; Luca Fontana; Antonio Bergamaschi; Marcelo Enrique Conti; Anna Pino; Daniela Mattei; Beatrice Bocca; Alessandro Alimonti
Journal:  Dose Response       Date:  2012-01-16       Impact factor: 2.658

2.  New Therapeutic Agent against Arterial Thrombosis: An Iridium(III)-Derived Organometallic Compound.

Authors:  Chih-Wei Hsia; Marappan Velusamy; Jeng-Ting Tsao; Chih-Hsuan Hsia; Duen-Suey Chou; Thanasekaran Jayakumar; Lin-Wen Lee; Jiun-Yi Li; Joen-Rong Sheu
Journal:  Int J Mol Sci       Date:  2017-12-05       Impact factor: 5.923

3.  Novel iridium (III)‑derived organometallic compound for the inhibition of human platelet activation.

Authors:  Kou-Gi Shyu; Marappan Velusamy; Chih-Wei Hsia; Chih-Hao Yang; Chih-Hsuan Hsia; Duen-Suey Chou; Thanasekaran Jayakumar; Joen-Rong Sheu; Jiun-Yi Li
Journal:  Int J Mol Med       Date:  2018-02-07       Impact factor: 4.101

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.